Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine in Acute Stroke "TRUST"

Completed

Phase 3 Results

Trial Description

To determine the value of oral nimodipine 120 mg per day for acute stroke.

Interventions

  • Nimodipine (Nimotop®)Drug
    Intervention Desc: Calcium channel blocker (L-type calcium channels)

Trial Design

Randomized, double-blind, placebo-controlled multicenter study of 1215 patients at 17 British centers.

Patient Involvement

Patients were randomized to receive 120 mg oral nimodipine (n=608) or placebo (n=607).

Outcomes

Type Measure Time Frame Safety Issue
Primary Independence after 6 months, defined as a score of 60 or more on the Barthel index.
Secondary Mortality, Nottingham ADL score, change in Orgogozo neurological score.